The Subcutaneous ICD – Should It be the first choice ICD therapy?

The Royal Society of Medicine is hosting a series of three webinars for Boston Scientific Limited. Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. Boston Scientific Limited is responsible for the content and delivery of the webinar.

This second webinar will provide the participants with an overview of Boston Scientific’s EMBLEM™ Subcutaneous ICD, the first and only extravascular ICD that offers protection from sudden cardiac death, without the risk of transvenous leads, with over 15 years of clinical data and nearing 100,000 implants globally.

Boston Scientific’s EMBLEM™ S-ICD is the first and only implantable defibrillator that leaves the heart and vasculature untouched. With both growing clinical evidence and clinical guidelines pointing to the use of S-ICD for a large population of ICD indicated patients, should the S-ICD be the first choice for many of our patients? 

This webinar will provide the participants with:

• Background on the S-ICD technology and patient selection
• Understanding of the risk of transvenous lead complications
• A review of the growing clinical evidence and guidelines for S-ICD usage
• The positive cost impact on our healthcare systems
• Advancements and the future direction of S-ICD therapy

This webinar is aimed at all healthcare professionals who may be responsible for referring or following up patients with an ICD. 

There will be an opportunity to ask questions to the panel during the webinar and the recording of the webinar will be made available to all registered delegates for 60 days after the live webinar.

Join in the conversation online
Follow us on Twitter: @RoySocMed

The content of the webinar has been put together and is being delivered by Boston Scientific Limited. The RSM is hosting the webinar – it has not had any involvement in the content or delivery of the programme.